Physician profile
Neera P Agarwal Antal
NPI 1811950751
$39,143.95
in general payments reported to CMS, 2019-2025
38 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $144 · 2021: $839 · 2022: $2,003 · 2023: $9,220 · 2024: $16K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $11K · Food and Beverage: $8,900 · Travel and Lodging: $1,125 · Honoraria: $260 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,800.00 |
| Consulting Fee | $11,167.50 |
| Food and Beverage | $8,900.34 |
| Travel and Lodging | $1,124.80 |
| Honoraria | $260.08 |
| Education | $171.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $16,537.74 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,683.24 | 2023-2024 | Spevigo, Cyltezo |
| Galderma Research & Development, LLC | $3,150.00 | 2023 | |
| Genentech USA, INC. | $2,498.12 | 2019-2025 | Xolair |
| Abbvie INC. | $1,924.56 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Verrica Pharmaceuticals INC. | $1,322.06 | 2023 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $1,201.55 | 2021-2025 | Sotyktu |
| Incyte Corporation | $901.93 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $725.45 | 2020-2025 | Adbry, Anzupgo, Spevigo |
| Pfizer INC. | $593.30 | 2022-2025 | |
| Dermavant Sciences, INC. | $580.38 | 2023-2024 | Vtama |
| Genzyme Corporation | $559.02 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $488.15 | 2021-2025 | Libtayo, Dupixent |
| Lilly USA, LLC | $436.85 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $427.90 | 2019-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $387.80 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $326.30 | 2019-2025 | Winlevi, Absorica Ld |
| Amgen INC. | $306.31 | 2022-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $286.88 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Pharmaceuticals, INC. | $235.27 | 2024-2025 | Libtayo, Dupixent |
| Arcutis Biotherapeutics, INC. | $169.78 | 2023-2024 | Zoryve |
| Organon LLC | $157.15 | 2023-2025 | Hadlima, Renflexis, Vtama |
| Krystal Biotech INC | $147.19 | 2023-2024 | Vyjuvek |
| Janssen Scientific Affairs, LLC | $143.70 | 2025 | Tremfya |
| Convatec INC. | $122.21 | 2023-2025 | |
| Epi Health, LLC | $115.94 | 2022 | |
| Mallinckrodt Hospital Products INC. | $114.14 | 2024-2025 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $99.29 | 2019-2023 | Jublia, Arazlo |
| Eli Lilly and Company | $99.00 | 2025 | |
| Almirall LLC | $81.10 | 2019-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $68.45 | 2022 | |
| Journey Medical Corporation | $59.09 | 2022 | |
| Organogenesis INC. | $59.03 | 2024 | |
| Mayne Pharma Commercial LLC | $35.52 | 2019-2024 | |
| Botanix Sb INC | $33.36 | 2025 | Sofdra |
| Biocon Biologics INC | $24.96 | 2024 | Hulio |
| Dermira, INC. | $24.02 | 2019 | |
| Kyowa Kirin, INC. | $17.21 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neera Agarwal Antal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.